Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Ovarian Cancer|Primary Peritoneal Cancer|Advanced Breast Cancer|Advanced Solid Tumors
Interventions: DRUG: BMN 673
Sponsor: National Cancer Institute (NCI)